Product Name :
SLLN-15
Description:
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
CAS:
2403650-93-9
Molecular Weight:
507.35
Formula:
C19H23N7Se2
Chemical Name:
N6-[(3S)-selenolan-3-yl]-N2-[4-(selenomorpholin-4-yl)phenyl]-7H-purine-2,6-diamine
Smiles :
C1[Se]CC[C@@H]1NC1=NC(NC2C=CC(=CC=2)N2CC[Se]CC2)=NC2N=CNC1=2
InChiKey:
KUGJLOYHZKIOSI-AWEZNQCLSA-N
InChi :
InChI=1S/C19H23N7Se2/c1-3-15(26-6-9-27-10-7-26)4-2-13(1)23-19-24-17-16(20-12-21-17)18(25-19)22-14-5-8-28-11-14/h1-4,12,14H,5-11H2,(H3,20,21,22,23,24,25)/t14-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Vunakizumab} web|{Vunakizumab} Interleukin Related|{Vunakizumab} Biological Activity|{Vunakizumab} Formula|{Vunakizumab} custom synthesis|{Vunakizumab} Epigenetic Reader Domain}
Shelf Life:
≥12 months if stored properly.{{5-Aminosalicylic Acid} web|{5-Aminosalicylic Acid} Metabolic Enzyme/Protease|{5-Aminosalicylic Acid} Technical Information|{5-Aminosalicylic Acid} In Vivo|{5-Aminosalicylic Acid} manufacturer|{5-Aminosalicylic Acid} Epigenetic Reader Domain}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).PMID:23618405 |Product information|CAS Number: 2403650-93-9|Molecular Weight: 507.35|Formula: C19H23N7Se2|Chemical Name: N6-[(3S)-selenolan-3-yl]-N2-[4-(selenomorpholin-4-yl)phenyl]-7H-purine-2,6-diamine|Smiles: C1[Se]CC[C@@H]1NC1=NC(NC2C=CC(=CC=2)N2CC[Se]CC2)=NC2N=CNC1=2|InChiKey: KUGJLOYHZKIOSI-AWEZNQCLSA-N|InChi: InChI=1S/C19H23N7Se2/c1-3-15(26-6-9-27-10-7-26)4-2-13(1)23-19-24-17-16(20-12-21-17)18(25-19)22-14-5-8-28-11-14/h1-4,12,14H,5-11H2,(H3,20,21,22,23,24,25)/t14-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner. SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines. Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.|In Vivo:|SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases. Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC.|Products are for research use only. Not for human use.|